Hong Kong, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Cre8 Enterprise Limited (Nasdaq: CRE) (“Cre8” or the “Company”), a Hong Kong-based integrated financial printing service provider, announced today that it is actively exploring strategic alliances with financial printing and compliance solution providers in Japan. These partnerships are intended to strengthen support for cross-border IPOs and dual listings, while enhancing the delivery of integrated solutions for multinational issuers. By leveraging local expert ...

TORONTO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Dundee Precious Metals Inc. (TSX:DPM) (“DPM”) today reported high-grade copper-gold-silver intercepts from its ongoing Serbian exploration program, including the Dumitru Potok prospect. Results included an intercept of 131.6 metres grading 3.93% CuEq, comprised of 1.53% Cu, 2.41 g/t Au and 12 g/t Ag from 1,126 metres and 76 metres at 2.47% CuEq, comprised of 1.01% Cu, 1.43 g/t Au and 10.37 g/t Ag from 1,277 metres downhole at hole DPDD032. This represents one of t ...

核心观点 - BXCL501在家庭环境中对双相情感障碍或精神分裂症相关躁动治疗显示出持续疗效和一致性益处 计划于2026年第一季度提交补充新药申请(sNDA)以扩大IGALMI®在门诊环境中的使用范围 [1][2][10] 临床试验设计 - SERENITY At-Home试验为关键性3期双盲安慰剂对照12周临床试验 旨在评估120 mcg剂量BXCL501在家庭环境中治疗躁动的安全性 [3][16] - 试验纳入246名随机患者 在215名患者中收集了2,628次躁动发作数据 其中2,437次发作在208名患者中得到治疗 [4] - 患者组成比例为45%双相情感障碍和55%精神分裂症 所有患者均能成功自行服用薄膜制剂 [4] 疗效结果 - 在2,433次治疗发作中 BXCL501在2小时时显示mCGI-S评分较基线平均降低显著优于安慰剂(p<0.05) [1][6] - 总体完全缓解率BXCL501组为50% 显著高于安慰剂组的33%(p<0.0001) [7] - 严重躁动发作完全缓解率BXCL501组为61% 显著高于安慰剂组的18%(p<0.0001) [7] - 中度躁动发作完全缓解率BXCL501组为43% 显著高于安慰剂组的34%(p<0.0005) [7] - 轻度躁动发作完全缓解率BXCL501组为60% 显著高于安慰剂组的40%(p<0.0001) [7] 持续疗效表现 - 首次12次给药后mCGI-S评分平均降低1.2 13次或更多给药后平均降低1.4 显示重复给药的持续益处 [8] - 在12周试验期间 第1-4周、5-8周和9-12周接受BXCL501治疗的躁动发作均显示mCGI-S评分平均降低1.3 [9] 市场机会与未满足需求 - 公司估计总可寻址市场为每年5700-7700万次躁动发作 显著高于先前估计的2300万次 [12] - 目前家庭环境中没有FDA批准的急性躁动治疗疗法 存在重大未满足医疗需求 [3][11] - 市场调查显示患者平均每月经历3-4次躁动发作 其中大部分为中度或重度 [12] 监管进展与计划 - 基于大量证据和FDA积极反馈 公司计划2026年第一季度提交sNDA以扩大IGALMI®在门诊环境中的使用 [1][2] - BXCL501于2018年12月获得快速通道资格认定 用于治疗双相情感障碍或精神分裂症相关躁动 [11] - 试验设计和方案已与FDA事先达成一致 [10] 产品背景 - IGALMI®(地塞米托咪定舌下薄膜)目前获FDA批准用于医疗监督环境下治疗双相情感障碍或精神分裂症相关躁动 [10][18] - BXCL501是一种研究性口服溶解薄膜制剂 为选择性α2肾上腺素能受体激动剂 [18] - 产品提供120 mcg和180 mcg两种剂量规格 [10]

OMA SAVINGS BANK PLC STOCK EXCHANGE RELEASE 10 SEPTEMBER 2025 AT 1.25 P.M. EET, OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE S&P Global Ratings affirmed Oma Savings Bank Plc's credit rating and changed outlook to negative On 10.9.2025 June 2025, S&P Global Ratings (S&P) has affirmed that the short-term and long-term issuer credit ratings of Oma Savings Bank Plc (OmaSp or the Company) remain unchanged and are BBB/A-2. At the same time, S&P has changed OmaSp's outlook from stable to nega ...

披露主体信息 - Man Group PLC作为披露方于2025年9月9日持有Spectris plc头寸[1] - 本次披露涉及标的公司为Spectris plc的5便士普通股[1][3] 持仓详情 - 通过现金结算衍生品持有1,178,432股Spectris普通股 占已发行股本1.19%[3] - 总持仓均为多头衍生品头寸 无实物股票持仓及空头头寸[3] - 未持有股票结算衍生品或认购权证[3][5] 交易活动 - 通过股权互换产品进行多笔增减仓操作 交易价格区间为40.9147-40.9400英镑[8] - 增持操作共3笔 合计3,795股 最高价40.9244英镑[8] - 减持操作共4笔 合计3,342股 最低价40.9109英镑[8] - 未进行实物股票交易及其他类型衍生品交易[7][9][10][11] 附加信息 - 披露日期为2025年9月10日 联系人为Molly Childs[14] - 不存在与要约相关的补偿安排或投票权协议[12][13] - 未附加开放式头寸补充表格[14]

FITUEYES FITUEYES Concludes a Successful Showcase at IFA Berlin 2025 BERLIN, Sept. 10, 2025 (GLOBE NEWSWIRE) -- FITUEYES, the design-forward creator of iconic TV stands and audio-visual furniture, successfully wrapped up its participation at IFA Berlin 2025, marking a milestone in its mission to redefine home entertainment and lifestyle design. Over the five-day event, FITUEYES welcomed thousands of visitors, journalists, and global partners. Showcasing Design Without Boundaries Unlike traditional TV st ...

STAFFORD, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that FDA has granted Fast Track designation for GLSI-100 in the HLA-A*02 patient population. The designation specifically states that "GLSI-100 for the treatment of patients with HLA-A*02 genotype and ...

SURREY, British Columbia, Sept. 10, 2025 (GLOBE NEWSWIRE) -- RecycLiCo Battery Materials Inc. (“RecycLiCo” or the “Company”) (TSX.V: AMY | OTCQB: AMYZF | FSE: ID4), a critical mineral refining and lithium-ion battery upcycling company, is pleased to welcome Mohammadali (Mo) Shahsavari as Materials Scientist and Process Engineer. Mr. Shahsavari’s appointment is part of RecycLiCo’s program to expand its in-house scientific and engineering foundation. He will play a key role in advancing the Company’s hydromet ...

HOMEWOOD, Ill., Sept. 10, 2025 (GLOBE NEWSWIRE) -- CN (TSX: CNR) (NYSE: CNI) Police officers will be available to members of the media during See Tracks? Think Train® Week from September 15-19, 2025. This annual public awareness campaign highlights the importance of safe behaviours near rail crossings and the danger of trespassing on railway property. Uniformed CN Police officers will be available for interviews across CN’s network in the United States and will take part in community events throughout the w ...

GRAND FALLS-WINDSOR, Newfoundland and Labrador, Sept. 10, 2025 (GLOBE NEWSWIRE) -- First Atlantic Nickel Corp. (TSXV: FAN) (OTCQB: FANCF) (FSE: P21) ("First Atlantic" or the "Company") is pleased to report a significant expansion of visible awaruite nickel-alloy mineralization at the RPM Zone, part of its 100% owned, district-scale, 30 kilometer-long Atlantic Nickel Project in Newfoundland (the "Atlantic Nickel Project" or the "Project"). RPM Drill hole AN-25-07, the second hole of the Phase 2 program, inte ...